Reference Lists
Epidemiology
Arfken, CL., Johanson, CE., Menza, S., Schuster, CR., Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. Journal of Substance Abuse Treatment 39, 96-104. 2010.
Ling W., Charuvastra C., Kaim S.C., Klett J. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry 33:709-720, 1976.
Ball J.C., Ross A. The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York, 1991; pages 166-168; 181-182.
Maxwell J, McCance-Katz EF: Indicators of methadone and buprenorphine use and abuse: What do we know? Am J Addict, 19:73-88, 2010.
Metzger D.S., Woody G., McLellan A. T., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18 month prospective follow-up. J Acquired Immune Deficiency Syndrome 6(9): 1049-1056, 1993.
Basic Pharmacology
Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Cowan A., Lewis J.W. (eds), Wiley-Liss, New York, 1995.
Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 36:115-121, 1994.
Cowan, A., Buprenorphine: the basic pharmacology revisited. J Addict Med. 1(2) 68-72. 2007.
Doxey J.C., Everitt J.E., Frank L.W., MacKenzie J.E. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. Br J Pharmacol 75(S):118P, 1982.
Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., Stitzer M.L. Buprenorphine’s physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459, 1996.
Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., Stitzer M.L. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81-91, 1997.
Gal T.J. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 45:66-71, 1989.
Greenwald, MK., Johanson, C., Moody, DE., Et al. Effects of buprenorphine maintenance dose on µ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology, 28, 2000-2009. 2003.
Iribarne C., Picart D., Dréano Y., Bail J.-P., Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sciences 60:1953-1964, 1997.
Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501-516, 1978.
Johnson R.E., Cone E.J., Henningfield J.E., Fudala P.J. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 46:335-343, 1989.
Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispo 26:818-821, 1998.
Lange W.R., Fudala P.J., Dax E.M., Johnson R.E. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 26:19-28, 1990.
Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther 223:30-39, 1982.
Nigam A.K., Ray R., Tripathi B.M. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treatment 10:391-394, 1993.
O'Connor J.J., Moloney E., Travers R., Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 83: 1085-1087, 1988.
Parran T.V., Adelman C.L., Jasinski D.R. A buprenorphine stabilization and rapid-taper protocol for the detoxification of opioid-dependent patients. Am J Addictions 3:306-313, 1994.
Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53: 570-576, 1993.
Preston K.L., Bigelow G.E., Liebson I.A. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 25:27-34, 1990.
Reynaud M., Tracqui A., Petit G., Potard D., Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combination. Am J Psychiatry 155:448-449, 1998.
Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 33: 81-86, 1993.
Sakol M.S., Stark C., Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow–An increase. Br J Addict 84: 439-441, 1989.
San L., Camà J., Fernández T., Ollé J.M., Peri J.M., Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br J Addiction 87:55-62, 1992.
Senay E.C., Dorus W., Goldberg F., Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectations. Arch Gen Psychiatry 34:361-367, 1977.
Thörn S.-E., Rawal N., Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet, 1(8578):179-180. 1988.
Walsh S.L., June H.L., Schuh K.J., Preston K.L., Bigelow G.E., Stitzer M.L. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacol 119:268-276, 1995.
Buprenorphine Metabolism
Chang Y, Moody DE, McCance-Katz EF: Novel metabolites of buprenorphine in human liver microsomes and human urine. Drug Metab and Dispos 34:440-8, 2006.
Fang WB, Chang Y, McCance-Katz EF, Moody DE: Determination of naloxone and nornaloxone (noroxymorphone) by high performance liquid chromatography- electrospray ionization -tandem mass spectrometry. J Anal Toxicol. 33(8):409-17, 2009.
Huang W, Moody DE, McCance-Katz EF: The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 28: 245-251, 2006.
Moody DE, Chang Y, Huang W, McCance-Katz EF: The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic & Clinical Pharmacology & Toxicology, 105: 211-215, 2009.
Applied Pharmacology
Ball J.C., Ross A.The Effectiveness of Methadone Maintenance Treatment.Springer-Verlag, New York, 1991; pages 166-168; 181-182.
Camà J., de Torres S., San L., Solé A., Guerra D., Ugena B. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clin Pharmacol Ther 38:336-341, 1985.
Charney D.S., Sternberg D.E., Kleber H.D., Heninger G.R., Redmond D.E. The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry 38:1273-1277, 1981.
Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 36:115-121, 1994.
Dole V.P., Nyswander M.A medical treatment for diacetylmorphine (heroin) addiction:A clinical trial with methadone hydrochloride. JAMA 193:80-84, 1965.
Eissenberg T., Bigelow G.E., Strain E.C., Walsh S.L., Brooner R.K., Stitzer M.L., Johnson R.E. Dose-related efficacy of levo-alpha acetyl methadol for treatment of opioid dependence: A randomized clinical trial. JAMA 277:1945-1951, 1997.
Finkle B.S., Jennison T.A., Chinn D.M., Ling W., Holmes E.D.Plasma and urine disposition of 1-alpha-acetylmethadol and its principal metabolites in man. J Analytic Toxicol 6:100-105, 1982.
Fraser H.F., Isbell H. Actions and addiction liability of alpha-acetylmethadols in man. J Pharmacol Exp Ther 105:458-465, 1952.
Freedman R.R., Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend 8:215-222, 1981.
Fudala P.J., Vocci F., Montgomery A., Trachtenberg A.I. Levomethadyl acetate (LAAM) for the treatment of opioid dependence: a multisite, open label study of LAAM safety and an evaluation of the product labeling and treatment regulations. J Maint Addictions 1:9-39, 1998.
Gold M.S., Redmond D.E., Kleber H.D. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2(8090):599-602, 1978.
Gordon N.B.Reaction-times of methadone treated ex heroin addicts. Psychopharmacol (Berl)16:337-344, 1970.
Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21:253-259, 1988.
Grabowski J., O'Brien C.P., Greenstein R., Ternes J., Long M., Steinberg-Donato S. Effects of contingent payment on compliance with a naltrexone regiment. Am J Drug Alcohol Abuse 6:355-365, 1979.
Gritz E.R., Shiffman S.M., Jarvik M.E., Haber J., Dymond A.M., Coger R., Charuvastra V., Schlesinger J.Physiological and psychological effects of methadone in man. Arch Gen Psychiatry 32:237-242, 1975.
Jaffe J.H., Schuster C.R., Smith B.B., Blachley P.H. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: a pilot study. JAMA 211:1834-1836, 1970.
Jaffe J.H., Senay E.C. Methadone and l-methadyl acetate: use in management of narcotic addicts. JAMA 216:1303-1305, 1971.
Jaffe J.H., Senay E.C., Schuster C.R., Renault P.R., Smith B., DiMenza S. Methadyl acetate vs methadone: a double-blind study in heroin users. JAMA 222:437-442, 1972.
Jones H.E., Strain E.C., Bigelow G.E., Walsh S.L., Stitzer M.L., Eissenberg T., Johnson R.E. Induction with LAAM: safety and efficacy. Arch Gen Psychiatry 55:729-736, 1998.
Judson B.A., Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts: I. Dosage schedule for induction and stabilization. Drug Alcohol Depend 4:461-466, 1979.
Judson B.A., Goldstein A., Inturrisi C.E. Methadyl acetate (LAAM) in the treatment of heroin addicts: II. Double-blind comparison of gradual and abrupt detoxification. Arch Gen Psychiatry 40:834-840, 1983.
Karp-Gelernter E., Savage C., McCabe O.L. Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study. Int J Addictions 17:805-813, 1982.
Keats A.S., Beecher H.K.Analgesic activity and toxic effects of acetylmethadol isomers in man. J Pharmacol Exp Ther 105:210-215, 1952.
Kleber H.D., Gold M.S., Riordan C.E. The use of clonidine in detoxification from opiates. Bull Narcotics 32:1-10, 1980.
Kreek M.J.Medical safety and side effects of methadone in tolerant individuals. JAMA 223:665-668, 1973.
Kreek M.J., Dodes L., Kane S., Knobler J., Martin R.Long-term methadone maintenance therapy: Effects on liver function. Ann Int Med 77:598-602, 1972.
Ling W., Charuvastra C., Kaim S.C., Klett J. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry 33:709-720, 1976.
Ling W., Klett J., Gillis R.D. A cooperative clinical study of methadyl acetate: I. Three-times-a-week regimen. Arch Gen Psychiatry 35:345-353, 1978.
Magura S., and Rosenblum A. "Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored." Mount Sinai Journal of Medicine 68.1 (2011): 62-74.
Marcovici M., O'Brien C.P., McLellan A.T., Kacian J. A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction. Am J Psychiatry 138:234-236, 1981.
McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P., The effects of psychosocial services in substance abuse treatment. JAMA 269:1953-9, 1993.
Mello N.K., Mendelson J.H., Kuehnle J.C., Sellers M.S.Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216:45-54, 1981.
National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry 35:335-340, 1978.
Nigam A.K., Ray R., Tripathi B.M. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treatment 10: 391-394, 1993.
Batki, S., TIP 43 Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. US Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Rockville, MD. 1993.
Rounsaville B.J., Kosten T., Kleber H. Success and failure at outpatient opioid detoxification: evaluating the process of clonidine- and methadone-assisted withdrawal. J Nerv Ment Dis 173:103-110, 1985.
Savage C., Karp E.G., Curran S.F., Hanlon T.E., McCabe O.L. Methadone/LAAM maintenance: a comparison study. Comp Psychiatry 17:415-424, 1976.
Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 54:713-720, 1997.
Senay E.C., Dorus W., Goldberg F., Thornton W.Withdrawal from methadone maintenance:Rate of withdrawal and expectations. Arch Gen Psychiatry 34:361-367, 1977.
Spencer L., Gregory M. Clonidine transdermal patches for use in outpatient opiate withdrawal. J Subst Abuse Treatment 6:113-117, 1989.
Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E.Methadone dose and treatment outcome. Drug Alcohol Depend 33:105-117, 1993.
Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E., Outcome after methadone treatment: Influence of prior treatment factors and current treatment status. Drug Alcohol Depend 35:223-230, 1994.
Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E.Randomized controlled trial of moderate versus high dose methadone in treatment of opioid dependence. JAMA 281:1000-1005, 1999.
Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279:524-538, 1996.
Washton A.M., Resnick R.B. Clonidine for opiate detoxification: outpatient clinical trials. Am J Psychiatry 137:1121-1122, 1980.
Washton A.M., Gold M.S., Pottash A.C. Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse 4:89-96, 1984.
Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501-516, 1978.
Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53:570-576, 1993.
Schuh K.J., Walsh S.L., Bigelow G.E., Preston K.L., Stitzer M.L. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836-846, 1996.
Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Therap 261: 985-993, 1992.
Strain E.C., Preston K.L. Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. J Pharmacol Exp Ther 272:628-638, 1995.
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580, 1994.
Fudala P.J., Yu E., Macfadden W., Boardman C., Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 50:1-8, 1998.
Kuhlman J.J., Lalani S., Magluilo J., Levine B., Darwin W.D., Johnson R.E., Cone E.J. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Analytic Toxic 20:369-378, 1996.
Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA. 304(14):1576-83. 2010.
Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA. 304(14):1576-1583. 2010.
Mendelson J., Jones R.T., Fernandez I., Welm S., Melby A.K., Baggott M.J. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 60:105-114, 1996.
Mendelson J., Upton R.A., Everhart E.T., Jacob P., Jones R.T. Bioavailability of sublingual buprenorphine. J Clin Pharm Ther 37:31-37, 1997.
Mendelson J., Jones R.T., Welm S., Brown J., Batki S.L. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 41:1095-1101, 1997.
Mendelson J., Jones R.T., Welm S., Baggott M., Fernandez I., Melby A.K., Nath R.P. Buprenorphine and naloxone combinations; the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacol 141:37-46, 1999.
Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., Mendelson J.E. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39:619-623, 1999.
Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent human volunteers. Psychopharmacol 94:484-490, 1988.
Schuh K.J., Johanson C.E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56:55-60, 1999.
Strain E.C., Walsh S.L., Preston K.L., Liebson I.A., Bigelow G.E. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacol 129:329-338, 1997.
Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacol 148:374-383, 2000.
Weinberg D.S., Inturrisi C.E., Reidenberg B., Moulin D.E., Nips T.J., Wallenstein S., Houde R.W., Foley K.M. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44:335-342, 1988.
White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 103(1-2):37-43. 2009.
Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Arch Intern Med. 171(5):425-31. 2011.
Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacol 136:217-225, 1998.
Amass, L., Bickel, W.K., Higgins, S.T., Hughes, J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J. Addict. Dis.13, 33-45, 1994.
Amass L., Bickel W.K., Higgins S.T., Badger G.J. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences 54:1215-1228, 1994.
Amass, L., Kamien, J.B., Mikulich, S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 58, 143-152, 2000.
Anderson F., Paluzzi P., Lee J., Huggins G., Svikis D.Illicit use of clonidine in opiate-abusing pregnant women. Obstet Gyneco l90:790-4, 1997.
Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78, 1988.
Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson RE. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247:47-53, 1988.
Bickel W.K., Amass L., Crean J.P., Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacol 146:111-118, 1999.
Conway T., Balson A.Concomitant abuse of clonidine and heroin. Southern Med J 86:954-956, 1993.
Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions J Sub Abuse Treatment 40(4): 349-356. 2011.
Diamant, K., Fischer, G., Schneider, C., Lenzinger, E., Pezawas, L., Schindler, S., Eder, H. Outpatient opiate detoxification treatment with buprenorphine: Preliminary investigation. Eur. Addict. Res. 4, 198-202. 1998.
Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., Stitzer M.L. controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81-91, 1997.
Fudala P.J., Jaffe J.H., Dax E.M., Johnson R.E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47:525-534, 1990.
Fudala PJ et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. NEJM 349:949-58, 2003.
Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict. 20(5):397-404. 2011.
Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. Addict Behav. 35(5):537-40. 2010.
Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W. Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse. 37(5):453-9. 2011.
Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750-2755, 1992.
Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40:17-25, 1995.
Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. Buprenorphine treatment of opioid dependence: Clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 40:27-35, 1995.
Kakko J et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361(9358):662-8, 2003.
Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181:358-364, 1993.
Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 24(2):226-32. 2009.
Ling W., Wesson D.R., Charuvastra C., Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401-407, 1996.
Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A., Santos E., Casadonte P., Fye C., Stine S., Wang R.I.H., Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93:475-486, 1998.
Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction. 104(2):256-65. 2009.
O'Connor, P.G., Carroll, K.M., Shi, J.M., Schottenfeld, R.S., Kosten, T.R., Rounsaville, B., Three methods of opiate detoxification in a primary care setting:A randomized trial. Ann. Inter. Med.127, 526-530. 1997.
Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 106(1):56-60. 2010.
Petry N.M., Bickel W.K., Badger G.J. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 66:306-314, 1999.
Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 39(4):340-52. 2010.
Rosen M.I., Wallace E.A., McMahon T.J., Pearsall R., Woods S.W., Price L.H., Kosten T.R. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 35:141-149, 1994.
Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011 Mar;89(3):443-9. Epub 2011 Jan 26.
Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025-1030, 1994.
Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacol 116: 401-406, 1994.
Tracqui, A., Kintz, P., Ludes, B. Buprenorphine-related deaths among drug addicts in France:A report on 20 fatalities.J. Analytic. Tox. 22, 430-434, 1998.
Winstock AR, Lintzeris N, Lea T. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment. Int J Drug Policy. 22(1):77-81. 2011.
Federal Register July 22, 1999; Volume 64, Number 140, pages 39809-39857.
Role of Non-Pharmacological Treatment
American Society of Addiction Medicine. Patient Placement Criteria for the Treatment of Substance-Related Disorders, Second Edition Revised (ASAM PPC-2R). ASAM, Chevy Chase, MD 2001
Carroll K.M.A Cognitive-Behavioral Approach: Treating Cocaine Addiction.Therapy Manuals for Drug Addiction, Manual 1.U.S. Department of Health and Human Services, National Institute on Drug Abuse, Rockville, Maryland, 1998.
Chapter 3 Brief Intervention in A Guide to Substance Abuse Services for Primary Care Clinicians. CSAT Treatment Improvement Protocol #24 DHHS Publication No. (SMA) 97-3139, pages 25-38
McLellan AT et al. The effects of psychosocial services in substance abuse treatment. JAMA 269(15):1953-9, 1993.
Narcotics Anonymous, Fifth Edition.World Service Office, Inc., Van Nuys, California, 1983.
Nowinski J et al. Twelve Step Facilitation Therapy Manual. NIAAA Project MATCH Monograph Series, Matteson M.E. (ed), Volume 1. U.S. Department of Health and Human Services, NIAAA, Rockville, MD 1994.
Prochaska JO, DiClemente CC, Morcross JC. In Search of How People Change: Applications to Addictive Behaviors. American Psychologist, 47(9); 1102-14. 1992.
Robles E., Silverman K., Stitzer M.L.Contingency Management Therapies.In:Methadone Treatment for Opioid Dependence, Strain E.C., Stitzer M.L. (eds).Johns Hopkins University Press, Baltimore, Maryland, 1999.
Psychiatric Co-Morbidities
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J.An inventory for measuring depression. Arch Gen Psychiatry 4:53-63, 1961.
Brooner R.K., King V.L., Kidorf M.S., Schmidt C.W., Bigelow G.E.Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54:71-80, 1997.
First M.B., Spitzer R.L., Gibbon M., Williams J.B.W.Structured Clinical Interview for DSM-IV Axis I Disorders -- Patient Edition (SCID-I/P, Version 2.0).Biometrics Research Department, New York State Psychiatric Institute, New York, NY10032, 1995.
Kessler, RC., Crum, RM., Warner, LA., Nelson, CB., Schulenberg, J., Anthony, JC., Lifetime co-occurance of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54(4): 313-321. 1997.
Khantzian E.J., Treece C.DSM-III psychiatric diagnosis of narcotic addicts. Arch Gen Psychiatry 42:1067-1071, 1985.
Kosten T.R., Morgan C., Kosten T.A. Depressive symptoms during buprenorphine treatment of opioid abusers. Journal of Substance Abuse Treatment 7: 51-54, 1990.
Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G.E. Imipramine treatment of opiate-dependent patients with depressive disorders. Arch Gen Psychiatry 55:153-160, 1998.
Rounsaville B.J., Anton S.F., Carroll K., Budde D., Prusoff B.A., Gawin F. Psychiatric diagnoses of treatment seeking cocaine abusers. Arch Gen Psychiatry 48:43-51, 1991.
Rounsaville B.J., Kosten T.R., Weissman M.M., Kleber H. Prognostic significance of psychopathology in treated opioid addicts: a 2.5 year follow-up study. Arch Gen Psychiatry 43:739-735, 1986.
Rounsaville B.J., Weissman M.M., Crits-Christoph K., Wilber C., Kleber H. Diagnosis and symptoms of depression in opioid addicts. Arch Gen Psychiatry 39:151-156, 1982.
Rounsaville B.J., Weissman M.M., Kleber H.D., Wilber C.Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry39:161-166, 1982.
Spitzer R.L., Kroenke K., Williams J.B.W., et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 272: 1749-1756, 1994.
Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 39(2):157-66. 2010.
Woody G.E., McLellan A.T., Luborsky L., O'Brien C.P., Sociopathy and psychotherapy outcome. Arch Gen Psychiatry 42(11):1081-1086, 1985.
Woody G.E., O’Brien C.P., McLellan A.T., Marcovici M., Evans B.D. The use of antidepressants with methadone in depressed maintenance patients. NYAS 120-127, 1982.
Medical Co-Morbidities
Alter M.J., et al. The prevalence of hepatitis C infection in the United States, 1988-1994. New England Journal of Medicine 341:556-62, 1999.
Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ: Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 9: 265-269, 2000.
Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Dependence 60:51-4. 2000.
Celentano D.D., Vlahov D., Cohn S., Shadle V.M., Obasanjo O., Moore R.D. Self-reported antiretroviral therapy in injection drug users. JAMA 280:544-546, 1998.
Coutinho R.A. HIV and hepatitis C among injecting drug users: success in preventing HIV has not been mirrored for hepatitis C. BMJ 317:424-5, 1998.
Curtis R., Friedman S.R., Neaigus A., Jose B., Goldstein M., Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep 109(3):319-27, 1994.
Delage G., Infante-Rivard C., Chiavetta J.A., Willems B., Pi D., Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study.Gastroenterology116:893-9, 1999.
Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E.Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.Am J Public Health 86:655-61, 1996.
Hecht F.M., Wilson I.B., Wu A.W., Cook R.L., Turner B.J. Optimizing care for persons with HIV infection. Annals of Internal Medicine 131:136-143, 1999.
Lucas G.M., Chaisson R.E., Moore R.D. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 131:81-87, 1999.
Malik A.H., Lee W.M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 132: 723-731, 2000.
Malotte C.K., Rhodes F., Mais K.E. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health 88(5):792-6, 1998.
Moatti: Prescription of buprenorphine may increase adherence to HAART among HIV+ opioid dependent patients. AIDS, 14:151-5. 2000.
Moreno S., Miralles P., Diaz M.D., et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: long-term effect on development of tuberculosis and survival. Arch Intern Med 157:1729, 1997.
Novick D.M., Reagan K.J., Croxson T.S., Gelb A.M., Stenger R.J., Kreek M.J. Hepatitis C virus serology in parenteral drug users with chronic liver disease. Addiction 92:167-71, 1997.
Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advancecd human immunodeficiency virus infection. New England Journal of Medicine 338:853-60, 1998.
Pulido F., Pena J.M., Rubio R., et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 157:227, 1997.
O'Connor P.G., Samet J.H. The substance-using human immunodeficiency virus patient: approaches to outpatient management. Am J Med 101(4):435-44, 1996.
O'Connor P.G., Selwyn P.A., Schottenfeld R.S. Medical progress: medical care for injection drug users with human immunodeficiency virus infection. N Engl J Med 331:450-459, 1994.
Reimer, J., Schulte, B., Castells, X., et al., Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clinical Infectious Disease. 40;S373-378. 2005.
Samet J.H., Stein M.D., O'Connor P.G. Models of medical care for HIV-infected drug users. Substance Abuse 16(3):131-139, 1995.
Strader, D., Wright, T., Thomas, D., Seeff, L., AASLD Practice Guideline, Diagnosis, management, and treatment of hepatitis C. Hepatology. 1147-1171.
Wodak A., Crofts N. Once more unto the breach: Controlling hepatitis C in injecting drug users. Addiction 91:181-4, 1996.
Drug-Drug Interactions
Alho, H., Sinclair, D., Vuori, E., Holopainen, A., Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend, 88:75-8, 2007.
Baker JR, Best AM, Pade PA, McCance-Katz EF: Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Annals of Pharmacother 40:392-6, 2006.
Baker J, Rainey PM, Moody DE, Morse E, Ma Q, McCance-Katz EF: Interactions between buprenorphine and antiretrovirals: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Am J Addict, 19: 17–29, 2010.
DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD: Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Journal of Pharmaceutical and Biomedical Analysis, 44:188-95, 2007
Gruber V, McCance-Katz EF: Methadone, buprenorphine and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep, 7(3):152-60, 2010.
Larance, B., Degenhardt, L., Lintzeris, N., Et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011. [E pub ahead of print]
McCance-Katz EF: Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women. Life Sci, 88(21-22):953-958. 2011
McCance-Katz EF: Treatment of opioid dependence and HIV/HCV co-infection in opioid dependent patients: the importance of drug interactions between opioids and antiretroviral medications. Clin Inf Dis, 41: S89-S95, 2005.
McCance-Katz EF, Jatlow P, Rainey P, Friedland G: Methadone effects on zidovudine (AZT) disposition (ACTG 262). J Acquir Immune Defic Syn Hum Retrovirol, 18: 435-443, 1998.
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland GH, Pade P, Rainey PM: Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug and Alcohol Dependence, 91:269-78, 2007
McCance-Katz EF, Moody DE, Morse G, Pade P, Friedland G, Baker J, Alvanzo A, Smith P, Abayomi O, Jatlow P, Rainey PM: Interactions between buprenorphine and antiretrovirals I: Non-nucleoside reverse transcriptase inhibitors I: efavirenz and delavirdine, Clin Infect Dis, 43 Suppl 4:S224-34, 2006.
McCance-Katz EF, Moody DE, Morse G, Pade P, Friedland G, Baker J, Alvanzo A, Smith P, Jatlow P, Rainey PM: Interactions between buprenorphine and antiretrovirals II: Protease inhibitors, nelfinavir, lopinavir/ritonavir, or ritonavir. Clin Infect Dis, 43 Suppl 4:S235-46, 2006.
McCance-Katz EF, Moody DE, Morse E, Ma Q, Rainey P: Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict, 19: 30–37, 2010.
McCance-Katz EF, Moody DE, Prathikanti S, Friedland GH, Rainey PM: Rifampin, but not rifabutin may produce opiate withdrawal in buprenorphine-maintained patients. Drug and Alcohol Dependence, in press.
McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addictions, 10: 296-307, 2001
McCance-Katz EF, Rainey PM, Moody DE: Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict, 19: 38-46, 2010.
McCance-Katz EF, Sullivan LS, Nallani S: Drug interactions of clinical importance between the opioids, methadone and buprenorphine, and frequently prescribed medications: A review. Am J Addictions, 19: 4–16, 2010.
Gender Differences
Moody DE, Fang WB, Morrison J, McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend. 2011 Apr 22. [Epub ahead of print]
Special Treatment Populations
Bogenschultz, MP., Abbott, PJ., Kushner, R., Tonigan, JS., Woody, GE., Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med. 4(4): 211-216. 2010
Boyer E, McCance-Katz EF, Marcus S: Methadone and buprenorphine toxicity in children. Am J Addict, 19: 89-97, 2010.
Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend. 107(2-3):253-6. 2010.
Meade, CS., Weiss, RD., Fitzmaurice, GM., et al., HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr. 55(1): 65-72. 2010.
Polsky, D., Glick, HA., Yang, J., Subramaniam, GA., Poole, SA., Woody, GE., Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 105(9)1616-1624. 2010
Schwartz R.H. Adolescent heroin use: a review. Pediatrics 102:1461-1466, 1998.
Subramaniam, GA., Fishman, MJ., Woody, G., Treatment of opioid-dependent adolescents and young adults with buprenorphine. Curr Psychiatry Rep. 11(5):360-363. 2009.
Woody, GE., Poole, SA., Subramaniam, G. et al., Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 300(17): 2003-2011. 2008.
Annitto W.J. Detoxification with buprenorphine of a pregnant heroin addict. Am J Addict 9:92-93, 2000.
Concheiro, M., Jones, HE., Johnson, RE., Choo, R., Huestis, MA., Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit. 2011 Epub ahead of print.
Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95:239-244, 2000.
Goodwin, RS., Wilkins, DG., Averin, O., Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. Clin Chem. 53(12):2136-2143. 2007.
Jarvis, M.A.E., Schnoll S.H. Methadone treatment during pregnancy. J. Psychoactive Drugs, 26(2), 155-161, 1994.
Johnson RE, Jones HE, Fischer G: Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug and Alcohol Dependence; 70: S87-S101. 2003.
Jones, HE., Johnson, RE., Jasinski, DR., Milio, L., Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend. 78(1):33-38. 2005.
Jones, HE., Johnson, RE., Milio, L., Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict. 15(3): 258-259. 2006.
Jones, HE., O’Grady, K., Dahne, J., Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse. 35(3):151-156. 2009.
Jones, HE., Martin, PR., Heil, SH., et al., Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 35(3): 245-259. 2008.
Jones H.E., Velez M.L., McCaul M.E., Svikis D.S. Special Treatment Issues for Women. In: Strain E.C., Stitzer M.L. (eds.) Methadone Treatment for Opioid Dependence, pp 251-280. Johns Hopkins University Press, Baltimore, Maryland, 1999.
Kacinko, SL., Jones, HE., Johnson, RE., Choo, RE., Concheiro-Guisan, M., Huestis, MA., Urinary excretion of buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin Chem. 55(6):1177-1187. 2009.
Lindemalm, S., Nydert, P., Svensson, J., Stahle, L., Sarman, I., Transfer of buprenorphine into breast milk and calculation of infant drug dose, J Hum Lact. 25(2):199-205.
Jannson, LM., Dipietro, JA., Velez, M., et al., Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 33(2): 240-3. 2010.
Jones, HE., Johnson, RE., Jasinski, DR., et al., Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79(1): 1-10. 2005.
Jones, HE., Kaltenbach, K., Heil, SH., et al., Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 363(24):2320-2331. 2010.
Jones, HE., Martin, PR., Heil, SH., Stine, SM., Kaltenbach, K., Selby, P., Coyle, MG., O’Grady, KE., Arria, AM., Fischer, G., Treatment of opioid-dependent pregnant women: Clinical and research issues, Journal of Substance Abuse Treatment Volume 35, Issue 3, October 2008, Pages 245-259
Virden, SF., The Relationship between infant feeding method and maternal role adjustment. J Nurse Midwifery 33(1): 31-5.1988.
Widstrom. AM., Wahlberg, V., Matthiesen, AS., Et al., Short-term effects of early suckling and touch of the nipple on maternal behavior. Early Hum Dev., 21(3) 153-63. 1990.
Cohen, R., Mrtek ,MB., Mrtek, RG., Comparisons of maternal absenteeism and infant illness rates among breast-feeding and formula-feeding women in two corporations, Am J Health Promot 10(2) 148-53. 1995.
Jansson, LM., Dipietro, JA., Elko, A.,Velez, M., Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med. 20 (9):677-85. 2007.
Abdel-Latif, ME., Pinner, J., Clews, S., Cooke, F., Lui, K., Oei, J.Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 117(6):e1163-9. 2006.
Malpas, TJ., Darlow, BA., Neonatal abstinence syndrome following abrupt cessation of breastfeeding. NZ Med J. 112(1080): 12-3.1999.
Johnson, RE., Jones, HE., Jasinski, DR., Et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 63(1):97-103. 2001.
Johnson, RE., Jones, HE., Fischer, G., Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 70(2) S87-101. 2003.
Blow F.C.Substance Abuse Among Older Adults.Treatment Improvement Protocol (TIP0 #26, U.S. Department of Health and Human Services, Center for Substance Abuse Treatment, Rockville, Maryland, 1998.
Avants S.K., Margolin A., DePhilippis D., Kosten T.R. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients: preliminary findings. J Subst Abuse Treatment 15:261-265, 1998.
Bruce RD, Kresina T, McCance-Katz EF: Medication assisted treatment and HIV/AIDS. AIDS. 24(3):331-40, 2010.
Iribarne C., Berthou F., Carlhant D., Dreano Y., Picart D., Lohezic F., Riche C. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispo 26:257-260, 1998.
Khalsa JH, Treisman G, McCance-Katz E, Tedaldi E.: Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Subst Abus. 29(3):5-16, 2008
Kresina TF, Bruce RD, McCance-Katz EF: Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Curr HIV Res 7(4):354-64, 2009.
Moatti J.P., Carrieri M.P., Spire B., Gastaut J.A., Cassuto J.P., Moreau J., and the Manif 2000 study group. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 14:151-155, 2000.
Montoya I.D., Umbricht A., Preston K.L. Buprenorphine for human immunovirus-positive opiate-dependent patients. Biol Psychiatry 38:131-136, 1995.
Current HIV treatment guidelines: www.hivatis.org
VI. Chronic pain patients:
Gureje O., Von Korff M., Simon G.E., Gater R.Persistent pain and well-being: a World Health Organization study in primary care. JAMA 280:147-51, 1998.
Hanks G.W. The clinical usefulness of agonist-antagonist opioid analgesics in chronic pain. Drug Alcohol Depend 20:339-346, 1987.
Wallenstein S.L., Kaiko R.F., Rogers A.G., Houde R.W. Crossover trials in clinical analgesic assays: studies of buprenorphine and morphine. Pharmacotherapy 6:228-235, 1986.
Treatment of Pain Model Policy: www.fsmb.org
Hand C.W., Sear J.W., Uppington J., Ball M.J., McQuay H.J., Moore R.A. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesthesia 74:276-282, 1990.
Summerfield R.J., Allen M.C., Moore R.A., Sear J.W., McQuay H.J. Buprenorphine in end stage renal failure. Anesthesia 40:914, 1985.
Patient Assessment/Selection
O’Connor P.G., Oliveto A.H., Shi J.M., Triffleman E., Carroll K.M., Kosten T.R., Rounsaville B.J.A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 22:523-31, 1996.
O’Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., Rounsaville B.J., Pakes J.A., Schottenfeld R.S.A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 105:100-5, 1998.
Clinical Management
A Guide to Substance Abuse Services for Primary Care Physician – TIP 24 from SAMHSA.
McNicholas, L: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A treatment improvement protocol (TIP 40). US DHHS, SAMHSA, CSAT, Rockville, MD, 2004.
McCance-Katz EF, Office-Based Buprenorphine Treatment for Opioid Dependent Patients. Harvard Review of Psychiatry, 12(6); 321-238. 2004.
Schottenfeld R.S., Pantalon, M.V., Assessment of the Patient (Chapter 12).In: Galanter M., Kleber H.D. Textbook of Substance Abuse Treatment, Second Edition. American Psychiatric Press, Washington, D.C., 1999.
Patient Confidentiality
Lopez, F. (ed) Confidentiality of Patient Records for Alcohol and Other Drug Treatment. Technical Assistance Publication #13, U.S. Department of Health and Human Services, Center for Substance Abuse Treatment, Rockville, Maryland, 1994.
Medical Record Keeping
Lopez, F. (ed) Confidentiality of Patient Records for Alcohol and Other Drug Treatment. Technical Assistance Publication #13, U.S. Department of Health and Human Services, Center for Substance Abuse Treatment, Rockville, Maryland, 1994.
Reference: Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office, 2002. Federation of State Medical Boards (www.fsmb.org)
